Sign in

CPMV on OTC

Mosaic ImmunoEngineering Inc.

Mosaic ImmunoEngineering Inc. is an American biological products company, incorporated in Delaware.1 It is headquartered in Huntington Beach, California.1 Its shares trade on OTC under the symbol CPMV.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCPMV on OTC1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersHuntington Beach, California1
  • Incorporated inDE2
  • Business address9114 Adams Ave., #202, Huntington Beach, Ca 926462
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Split. On December 30, 2020, we changed our fiscal year end from May 31 to December 31.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$616.1K in 2025−82% since 2021
-$4.0M-$3.0M-$2.0M-$1.0M02021: -$3.5M-$3.5M20212022: -$2.6M-$2.6M2022−25%2023: -$1.4M-$1.4M2023−47%2024: -$879.7K-$879.7K2024−37%2025: -$616.1K-$616.1K2025−30%
Net income84567-$687.8K in 2025−14% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$798.5K-$798.5K20192020: -$1.1M-$1.1M2020+33%2021: -$3.7M-$3.7M2021+247%2022: -$2.4M-$2.4M2022−35%2023: -$1.0M-$1.0M2023−58%2024: -$922.0K-$922.0K2024−9%2025: -$687.8K-$687.8K2025−25%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development$64.0K$183.9K
General and administrative$552.1K$695.8K
Total operating expenses$616.1K$879.7K
Loss from operations-$616.1K-$879.7K
Other income$14.0K$42.0K
Interest income$6$5
Interest expense on loan payable-$10.0K-$7.0K
Non-cash interest expense on convertible notes-$73.3K-$73.5K
Accretion to redemption value on convertible notes$0-$1.4K
Total other income, net-$69.3K-$39.9K
Loss before provision for income taxes-$685.4K-$919.6K
Provision for income taxes$2.4K$2.4K
Net loss-$687.8K-$922.0K
Basic loss per common share-$0.10-$0.13
Diluted loss per common share-$0.10-$0.13
Weighted average number of common shares outstanding basic7.2M shares7.2M shares

Compare Mosaic ImmunoEngineering Inc. with another company

What it owns

What Mosaic ImmunoEngineering Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.6K7 Dec 31, 2025$115.0K7 Dec 31, 2024−96.9%

Properties, in its own words

The Company has no properties at December 31, 2025, and at the period covered by this Report, has no agreements to acquire any properties. The Company currently uses the home offices of management at no cost to the Company. The Company expects this arrangement to continue until the Company can raise sufficient capital and potentially license or acquire new technologies.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led Mosaic ImmunoEngineering Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Pohl2006–2007
  2. Frederick C. Goerner2008
  3. Clifford L. Flowers2010–2013

Chief financial officer

  1. Thomas J. Sweeney2006–2007
  2. Clifford L. Flowers2007–2015
  3. Paul J. Lytle2020–2021
2010201520202025
Board members and other officers (15)

Former names

  • PATRIOT SCIENTIFIC CORPDec 11, 1995 to Nov 19, 20202

Timeline

  1. Jan 2, 20258-K Other events31
  2. Jul 25, 20248-K Executive or director change32
  3. May 31, 20248-K Executive or director change33
  4. May 21, 20248-K Change of auditor34
  5. Apr 29, 20248-K Regulation FD disclosure; Other events35
  6. Apr 19, 20248-K Executive or director change36
  7. Mar 28, 20248-K Entered a material agreement; Ended a material agreement37
  8. Jun 26, 20238-K Entered a material agreement; Other events38
  9. May 3, 20238-K Executive or director change39
  10. Jul 12, 20228-K Entered a material agreement40
  11. May 5, 20228-K Entered a material agreement; Regulation FD disclosure41
  12. Feb 22, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares42
  13. Jun 7, 2010New chief executive Clifford L. Flowers becomes CEO13
  14. Mar 12, 2008New chief executive Frederick C. Goerner becomes CEO14
  15. Apr 17, 2006New chief executive David Pohl becomes CEO15

Filings

47 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 12 major events, 5 insider forms, 10 other. The latest 20:

  1. Aug 14, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
  2. May 20, 202610-Q FORM 10-Q FOR MAR 2026 EDGAR
  3. May 15, 2026NT 10-Q 10-Q EXTENSION FOR MARCH 2026 EDGAR
  4. Apr 15, 202610-K FORM 10-K FOR DEC 2025 EDGAR
  5. Mar 31, 2026NT 10-K NOTICE OF LATE FILING EDGAR
  6. Nov 19, 202510-Q FORM 10-Q FOR SEPT 2025 EDGAR
  7. Nov 12, 2025NT 10-Q EXTENSION EDGAR
  8. Aug 19, 202510-Q FORM 10-Q FOR JUNE 2025 EDGAR
  9. Aug 12, 2025NT 10-Q EXTENSION EDGAR
  10. May 20, 202510-Q FORM 10-Q FOR MAR 2025 EDGAR
  11. May 15, 2025NT 10-Q EXTENSION EDGAR
  12. Apr 15, 202510-K FORM 10-K FOR DEC 2024 EDGAR
  13. Mar 28, 2025NT 10-K EXTENSION FOR 10-K 2024 EDGAR
  14. Jan 2, 20258-K EDGAR
  15. Nov 19, 202410-Q FORM 10-Q FOR SEPT 2024 EDGAR
  16. Nov 13, 2024NT 10-Q 10-Q EXTENSION EDGAR
  17. Aug 14, 202410-Q FORM 10-Q FOR JUNE 2024 EDGAR
  18. Jul 25, 20248-K EDGAR
  19. May 31, 20248-K EDGAR
  20. May 21, 20248-K EDGAR

The 47 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Mosaic ImmunoEngineering Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMosaic ImmunoEngineering Inc.1
  • CIK0000836564
  • Employer ID (EIN)84-10702783
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9114 Adams Ave., #202, Huntington Beach, CA 926461
  • Phone657-208-08901
  • Shares outstanding7,242,137 as of Aug 14, 202610
  • Public float$856.0K as of Jun 30, 20253
  • AuditorRose, Snyder & Jacobs LLP, Encino, California PCAOB ID 468; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceDec 11, 19951
  • Filings553 in all: 4 (129), 8-K (114), 10-Q (67), 10QSB (26), 10-K (21), NT 10-Q (21), DEF 14A (20), 3 (13)1
    All 43 form types

    S-8 (13), SB-2/A (13), 8-K/A (9), 10QSB/A (8), REGDEX (8), PRE 14A (7), SB-2 (7), NT 10-K (6), 10KSB40 (5), S-1 (5), S-3 (5), 10KSB (4), CORRESP (4), CT ORDER (4), S-1/A (4), 10KSB/A (3), EFFECT (3), NO ACT (3), SC 13G (3), SC 13G/A (3), UPLOAD (3), 4/A (2), 424B1 (2), DEF 14C (2), DEFA14A (2), PRE 14C (2), RW (2), S-3/A (2), S-8 POS (2), 10-KT (1), D (1), DEFR14A (1), POS AM (1), PRER14A (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 18, 2018
    Latest 8-K (8-K) Jan 2, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.00001 par value

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Mosaic ImmunoEngineering Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 40 risks under these headings, as written.3

  • Unless the context otherwise requires, references to the “Company,” the “combined company,” “Mosaic,” “we,” “our,” or “us” in this Report refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries (formerly known as Patriot Scientific Corporation). References to “PTSC” refer to Patriot Scientific Corporation prior to the completion of the Reverse Merger and references to “Private Mosaic” refer to privately held Mosaic ImmunoEngineering, Inc. prior to the completion of the Reverse Merger.
  • Risks Related to Our Operations
  • While the Company’s financial statements have been prepared on a going concern basis, we do not currently have sufficient working capital to fund our existing liabilities or any planned operations for the next twelve months and we may be required to cease our operations altogether if we are unable to secure sufficient funding.
  • We entered into a binding term sheet with Oncotelic Therapeutics, Inc. to acquire rights to certain technologies of Oncotelic and we may not enter into a definitive agreement if certain conditions are not met.
  • If we enter into a definitive agreement with Oncotelic under the terms of the binding term sheet, existing stockholders will experience substantial immediate dilution.
  • We currently have no development pipeline and we may not successfully identify, license or acquire new product candidates.
  • If we are able to raise sufficient capital and successfully identify new product candidates, we expect that we will incur significant losses over the next several years and may never achieve or maintain profitability.
  • Our development efforts have historically been with product candidates in early-stage preclinical development.
  • Our short operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.
  • Business interruptions resulting from the coronavirus disease (COVID-19) outbreak or similar public health crises could cause a disruption of the development of product candidates and adversely impact our business.
  • The Company and its subsidiaries have limited insurance for their operations and are subject to various risks of loss.
  • If we successfully identify new product candidates and license those rights, then drug development will involve a lengthy and expensive process with an uncertain outcome, including failure to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the product manufacturing of any potential product candidates.
The other 29 risks
  • If serious adverse events or unacceptable side effects are identified during the development of any product candidates, we may need to abandon or limit our development of those future product candidates.
  • Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our or third parties’ cyber security.
  • If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.
  • Risks Related to Our Financial Position and Need for Additional Capital
  • We will need substantial additional funding. If we are unable to secure sufficient capital in the near term, we may be required to cease operations.
  • Raising capital will cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.
  • Because the Reverse Merger resulted in an ownership change under Section 382 of the Internal Revenue Code for PTSC, PTSC’s pre-merger net operating loss carryforwards and certain other tax attributes may be subject to limitations. In addition, if we enter into a definitive agreement with Oncotelic, we would experience a greater than 50% change in ownership that could cause further limitations on our net operating loss carryforwards.
  • Risks Related to Our Dependence on Third Parties
  • Future development collaborations may be important to us. If we are unable to enter into or maintain these collaborations, or if these collaborations are not successful, our business could be adversely affected.
  • We may contract with third parties for the manufacture of product candidates for preclinical and clinical studies and may expect to continue to do so for commercialization. This potential reliance on third parties increases the risk that we will not have sufficient quantities of product candidates or products at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts.
  • Data provided by collaborators and other parties upon which we rely has not been independently verified and could turn out to be inaccurate, misleading, or incomplete.
  • Risks Related to Intellectual Property
  • If we are able to raise sufficient capital and potentially license or acquire new technologies, we may be unable to obtain and maintain intellectual property protection for these technologies or products we plan to license or develop or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.
  • If we successfully identify new product candidates and license those rights, we may fail to comply with our obligations under any potential license in which we may license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our future licensors, and we could lose those rights or other rights which could be the products upon which our business depends.
  • If we successfully identify new product candidates and license those rights, we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
  • We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • Risks Related to Our Employee Matters, Managing Growth and Macroeconomic Conditions
  • If we successfully identify new product candidates and license those rights, then our future success will also depend on our ability to attract, hire, retain and motivate executives, key employees, and our general workforce.
  • If we successfully identify new product candidates and license those rights, then we expect to expand our research and development function, as well as our corporate operations, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • We may face risks related to securities litigation that could result in significant legal expenses and settlement or damage awards.
  • Risks Related to Our Common Stock
  • There is a substantial lack of liquidity of our common stock and volatility risks, and because there is no active public trading market for our common stock, you may not be able to resell your common stock.
  • The market for our common stock is subject to rules relating to low-priced stock (“Penny Stock”) which may limit our ability to raise capital.
  • FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our common stock.
  • Future sales of shares by existing stockholders could cause the Company’s stock price to decline.
  • We expect our stock price to be volatile, and the market price of our common stock may drop unexpectedly.
  • Our share price could decline as a result of short sales.
  • We may issue preferred stock, and the terms of such preferred stock may reduce the value of our common stock.
  • Our executive officers, directors and principal stockholders, if they choose to act together, will have the ability to control all matters submitted to stockholders for approval.
  • Our amended and restated certificate of incorporation and amended and restated bylaws provides that state or federal court located within the state of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit its stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
  • Anti-takeover provisions contained in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt.
  • We do not expect to pay any cash dividends in the foreseeable future.

Legal proceedings

Information pertaining to legal proceedings is provided in Note 10, Commitments and Contingencies, to the accompanying audited consolidated financial statements and is incorporated by reference herein.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42